Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
Kashif Ali, Gary Berman, Honghong Zhou, Weiping Deng, Veronica Faughnan, Maria Coronado-Voges, Baoyu Ding, Jacqueline Dooley, Bethany Girard, William Hillebrand, Rolando Pajon, Jacqueline M Miller, Brett Leav, Roderick McPhee, Kashif Ali, Gary Berman, Honghong Zhou, Weiping Deng, Veronica Faughnan, Maria Coronado-Voges, Baoyu Ding, Jacqueline Dooley, Bethany Girard, William Hillebrand, Rolando Pajon, Jacqueline M Miller, Brett Leav, Roderick McPhee
Abstract
Background: The incidence of coronavirus disease 2019 (Covid-19) among adolescents between 12 and 17 years of age was approximately 900 per 100,000 population from April 1 through June 11, 2021. The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in adolescents are unknown.
Methods: In this ongoing phase 2-3, placebo-controlled trial, we randomly assigned healthy adolescents (12 to 17 years of age) in a 2:1 ratio to receive two injections of the mRNA-1273 vaccine (100 μg in each) or placebo, administered 28 days apart. The primary objectives were evaluation of the safety of mRNA-1273 in adolescents and the noninferiority of the immune response in adolescents as compared with that in young adults (18 to 25 years of age) in a phase 3 trial. Secondary objectives included the efficacy of mRNA-1273 in preventing Covid-19 or asymptomatic severe acute respiratory syndrome coronavirus 2 infection.
Results: A total of 3732 participants were randomly assigned to receive mRNA-1273 (2489 participants) or placebo (1243 participants). In the mRNA-1273 group, the most common solicited adverse reactions after the first or second injections were injection-site pain (in 93.1% and 92.4%, respectively), headache (in 44.6% and 70.2%, respectively), and fatigue (in 47.9% and 67.8%, respectively); in the placebo group, the most common solicited adverse reactions after the first or second injections were injection-site pain (in 34.8% or 30.3%, respectively), headache (in 38.5% and 30.2%, respectively), and fatigue (in 36.6% and 28.9%, respectively). No serious adverse events related to mRNA-1273 or placebo were noted. The geometric mean titer ratio of pseudovirus neutralizing antibody titers in adolescents relative to young adults was 1.08 (95% confidence interval [CI], 0.94 to 1.24), and the absolute difference in serologic response was 0.2 percentage points (95% CI, -1.8 to 2.4), which met the noninferiority criterion. No cases of Covid-19 with an onset of 14 days after the second injection were reported in the mRNA-1273 group, and four cases occurred in the placebo group.
Conclusions: The mRNA-1273 vaccine had an acceptable safety profile in adolescents. The immune response was similar to that in young adults, and the vaccine was efficacious in preventing Covid-19. (Funded by Moderna and the Biomedical Advanced Research and Development Authority; Teen COVE ClinicalTrials.gov number, NCT04649151.).
Copyright © 2021 Massachusetts Medical Society.
Figures
References
- World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard June 7, 2021. ().
- Wallace M, Oliver S. COVID-19 mRNA vaccines in adolescents and young adults: benefit-risk discussion. Atlanta: Centers for Disease Control and Prevention. June 23, 2021. ().
- Davies NG, Klepac P, Liu Y, et al.. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med 2020;26:1205-1211.
- Havers FP, Whitaker M, Self JL, et al. Hospitalization of adolescents aged 12–17 years with laboratory-confirmed COVID-19 — COVID-NET, 14 states, March 1, 2020–April 24, 2021. MMWR Morb Mortal Wkly Rep 2021;70:851-857.
- Penner J, Abdel-Mannan O, Grant K, et al. 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study. Lancet Child Adolesc Health 2021;5:473-482.
- Monod M, Blenkinsop A, Xi X, et al. Age groups that sustain resurging COVID-19 epidemics in the United States. Science 2021;371(6536):eabe8372-eabe8372.
- Swedo E, Idaikkadar N, Leemis R, et al. Trends in U.S. emergency department visits related to suspected or confirmed child abuse and neglect among children and adolescents aged <18 years before and during the COVID-19 pandemic — United States, January 2019–September 2020. MMWR Morb Mortal Wkly Rep 2020;69:1841-1847.
- Usher K, Bhullar N, Durkin J, Gyamfi N, Jackson D. Family violence and COVID-19: increased vulnerability and reduced options for support. Int J Ment Health Nurs 2020;29:549-552.
- Baron EJ, Goldstein EG, Wallace CT. Suffering in silence: how COVID-19 school closures inhibit the reporting of child maltreatment. J Public Econ 2020;190:104258-104258.
- European Centre for Disease Prevention and Control. SARS-CoV-2 transmission and children, 2021. ().
- Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020;383:2427-2438.
- Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med 2020;383:1920-1931.
- Doria-Rose N, Suthar MS, Makowski M, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med 2021;384:2259-2261.
- Chu L, McPhee R, Huang W, et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine 2021;39:2791-2799.
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403-416.
- Food and Drug Administration. Moderna COVID-19 vaccine. June 7, 2021. ().
- Centers for Disease Control and Prevention. Symptoms of COVID-19, 2021. ().
- Chua GT, Wong JSC, Lam I, et al. Clinical characteristics and transmission of COVID-19 in children and youths during 3 waves of outbreaks in Hong Kong. JAMA Netw Open 2021;4(5):e218824-e218824.
- Hobbs CV, Martin LM, Kim SS, et al. Factors associated with positive SARS-CoV-2 test results in outpatient health facilities and emergency departments among children and adolescents aged <18 years — Mississippi, September–November 2020. MMWR Morb Mortal Wkly Rep 2020;69:1925-1929.
- Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr 2021;175:143-156.
- Zimmerman KO, Akinboyo IC, Brookhart MA, et al. Incidence and secondary transmission of SARS-CoV-2 infections in schools. Pediatrics 2021;147(4):e2020048090-e2020048090.
- Kim L, Whitaker M, O’Halloran A, et al. Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19 — COVID-NET, 14 states, March 1–July 25, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1081-1088.
- Frenck RW Jr, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med 2021;385:239-250.
- Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic. May 10, 2021. ().
- Shimabukuro T. COVID-19 vaccine safety updates. Atlanta: Centers for Disease Control and Prevention. June 23, 2021. ().
- Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 2020;383:2439-2450.
Source: PubMed